2019 has been quite a year and my blog views are the highest they have ever been. They could have been even higher had I written more articles instead of resting on my laurels after reaching ONE MILLON total views in June of this year. Will try harder in 2020! (edit – COVID changed those plans)
Things are so hectic I might need to think about more resources for my website/blog going forward. Much of the effort in 2019 has been directed in building up my private group, the fastest growing NET group on earth and based on current size and growth rate, it will soon be the biggest (edit: it is now). I also need more resources in the private group, not just more moderators (any volunteers?) but also more very knowledgeable patients who also believe in the principles on which the private group has been established and now runs.
Of the approximately 370,000 views of my blog site in 2019, the top 10 articles account for almost 100,000. They are a mix of my top awareness posts and the posts which are popular with patients and their supporters, mainly because they are so helpful (I’m told).
Thanks for supporting me in 2019, I hope to improve my services to you in 2020, in particular via my website (which will contain my blog articles and other useful stuff).
To read these articles, click on the title or the picture:
2. Living with Neuroendocrine Cancer – a site by Ronny Allan
3. Neuroendocrine Cancer: A Witch’s Brew (Clinical Esoterica)
4. Diagnosed with Neuroendocrine Cancer? – 10 questions to ask your doctor (and where to find a NET Specialist Worldwide)
5. Neuroendocrine Cancer – Ronny Allan: Background to my Diagnosis and Treatment
6. Neuroendocrine Neoplasms – Grade and Stage (incorporating WHO 2019 changes)
7. The Syndromes of Neuroendocrine Cancer – Early Signs of a Late Diagnosis
8. Neuroendocrine Cancer – tumour markers and hormone levels
9. Pancreatic Cancer vs Neuroendocrine Tumours of Pancreatic origin
10. Steve Jobs – the most famous Neuroendocrine Cancer Ambassador we NEVER had
Thanks for reading.
I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Prospective phase II trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT imaging of integrin for prognostication in patients with neuroendocrine neoplasms
August 25, 2022 — A new gallium-68 PET radiotracer appears effective for predicting higher risk of disease progression and mortality in patients with neuroendocrine tumors,
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial
One of the most controversial subjects in Neuroendocrine Neoplasms is the management of small non-functional (asymptomatic) pancreatic NETs (NF-PanNEN). In the most general terms, surgery
Eat that doughnut!
I was recently reminded of a post I wrote called “The Other 5 Es”. I later changed the name to “The 6 Es”. The reason
Clinical Trial: Phase 1b/3 Targeted Alpha-Emitter PRRT RYZ101 (Ac225)
What is RYZ101? RYZ101 is an investigational targeted alpha-emitter radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2. RYZ101
Neuroendocrine Cancer: When you get years added to your life, it’s important to get life added to your years
Self Pity or Self Help? I’m not one for wallowing in self-pity or accepting invites to pity parties. It’s not my style. Things happen in
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST) Neuroendocrine
